Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 9 February 2026(2 announcements)
Zydus Lifesciences reported Q3 FY26 revenue from operations of ₹68,645 mn, up 30% YoY, with adjusted net profit of ₹11,109 mn, up 9% YoY. For 9M FY26, revenues reached ₹1,95,614 mn, up 17% YoY, and adjusted net profit was ₹38,640 mn, up 15% YoY. EBITDA margins improved to 30.3% (9M, +80 bps YoY). Key drivers included North America formulations growth of 16% YoY, Consumer Wellness surge of 113% YoY, and International Markets formulations up 38% YoY. The company strengthened its innovation pipeline with orphan drug approval and specialty portfolio expansion.
Zydus Lifesciences reported Q3 FY26 revenues of ₹68,645 million, up 30% YoY, driven by robust pharmaceutical business growth across India formulations (13% YoY), North America (16.4% YoY), and International Markets (38.2% YoY). EBITDA reached ₹18,164 million with margin at 26.5%, up 20 bps YoY. Adjusted net profit grew 8.5% YoY to ₹11,109 million. Consumer Wellness surged 113% YoY following Comfort Click Limited consolidation. Regulatory approvals included Nufymco® biosimilar and Zycubo® for Menkes disease. Net debt improved to ₹28,728 million from negative ₹48,880 million year-ago.
About Zydus Lifesciences Limited (ZYDUSLIFE)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when ZYDUSLIFE files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track ZYDUSLIFE — Free💡 Ask AI about this filing
📊 More ZYDUSLIFE filings
- Announcement — 12 August 2026 Zydus Lifesciences announced that its scheduled participation in the Motilal Oswal Global Investor C...
- 🔴 Financial Results — 11 August 2026 Zydus Lifesciences reported Q1 FY27 revenue of **₹80,170 crores**, up 22% YoY, but net profit fell 3...
- 🟡 Board Meeting — 11 August 2026 Zydus Lifesciences announced its Q1 FY2026 unaudited financial results approved on August 11, 2026, ...
- 🔴 Financial Results — 11 August 2026 Zydus Lifesciences reported total revenues of Rs. 80,170 million for Q1 FY27, reflecting a 22% year-...
- 🟡 Board Meeting — 11 August 2026 Zydus Lifesciences reappointed Dr. Sharvil Patel as Managing Director for five years starting April ...
🔥 Also filed on 9 February 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ZYDUSLIFE files new disclosures
Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ZYDUSLIFE — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research